Abstract
Hypertyrosinemia results from abnormality in tyrosine metabolism. Acquired hypertyrosinemia is notably more common than inherited types and typically presents with profile suggestive of secondary aetiology on biochemical testing. Herein, we present an unusual case of a day 16-of-life baby girl who was screened for inborn errors of metabolism (IEM). She presented with jaundice, hypotonia, lethargy and had hepatomegaly on examination. She was treated for sepsis with multiorgan involvement, requiring escalation of intravenous antibiotics and assisted ventilation. Her dried blood spot (DBS) showed moderate elevation of tyrosine (408umol/L, N:10-182) with low Phe:Tyr ratio (0.15mmol/L, N:0.32-3.45). Plasma amino acid showed isolated hypertyrosinemia at 807mmol/L (N:5-167) with mild, non-significant elevations of other liver metabolites. No succinylacetone peak seen with urine organic acids, making the diagnosis of inherited Tyrosinemia type I less likely despite the characteristic findings from DBS, plasma amino acids, and presenting clinical signs. Repeated IEM screening two weeks later revealed a non-diagnostic profile across both DBS and plasma amino acids in light of resolving sepsis and clinical improvement. This case highlights the challenges associated with incompatible biochemical testing in a child with a high index of suspicion for inherited Tyrosinemia. In our case, repeated screening ruled out inherited Tyrosinemia, suggesting the initial picture of hypertyrosinemia to be likely due to liver dysfunction and impaired activity of liver enzymes that are responsible for tyrosine catabolism.
References
Adnan, M., & Puranik, S. (2022). Hypertyrosinemia. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing LLC. Retrieved from:
https://www.ncbi.nlm.nih.gov/books/NBK578205/
Alsharhan, H., & Ficicioglu, C. (2020). Disorders of phenylalanine and tyrosine metabolism. Translational Science of Rare Diseases, 5(1–2), 3–58.
https://doi.org/10.3233/trd-200049
El-Shabrawi, M., & Kamal. (2013). Current management options for tyrosinemia. Orphan Drugs: Research and Reviews, 1.
https://doi.org/10.2147/odrr.s31501
Kawabata, K., Kido, J., Yoshida, T., Matsumoto, S., & Nakamura, K. (2022). A case report of two siblings with hypertyrosinemia type 1 presenting with hepatic disease with different onset time and severity. Molecular Genetics and Metabolism Reports, 32, 100892.
https://doi.org/10.1016/j.ymgmr.2022.100892
Morrow, G., & Tanguay, R. M. (2017). Biochemical and clinical aspects of hereditary tyrosinemia type 1. In Advances in Experimental Medicine and Biology (Vol. 959, pp. 9–21). Springer New York LLC.
https://doi.org/10.1007/978-3-319-55780-9_2
Paulusma, C. C., Lamers, W. H., Broer, S., & van de Graaf, S. F. J. (2022, July 1). Amino acid metabolism, transport and signalling in the liver revisited. Biochemical Pharmacology. Elsevier.
https://doi.org/10.1016/j.bcp.2022.115074
Soans, S. T., & Panambur, S. (2019). Sepsis mimics. Pediatric Infectious Disease, 1(4), 145–147.
https://doi.org/10.5005/jp-journals-10081-1217
Van Spronsen, F. J., Burlina, A., & Vici, C. D. (2022). Tyrosine Metabolism. In Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases, Second Edition (pp. 353–364). Springer International Publishing.
https://doi.org/10.1007/978-3-030-67727-5_21
Zhang, W., Yang, Y., Peng, W., Chang, J., Mei, Y., Yan, L., … Feng, Z. (2020). A 7-Year Report of Spectrum of Inborn Errors of Metabolism on Full-Term and Premature Infants in a Chinese Neonatal Intensive Care Unit. Frontiers in Genetics, 10, 460730.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Array